Form 8-K - Current report:
SEC Accession No. 0001193125-24-284214
Filing Date
2024-12-23
Accepted
2024-12-23 16:30:54
Documents
13
Period of Report
2024-12-18
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d911298d8k.htm   iXBRL 8-K 27919
  Complete submission text file 0001193125-24-284214.txt   151330

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fulc-20241218.xsd EX-101.SCH 2858
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20241218_lab.xml EX-101.LAB 17980
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20241218_pre.xml EX-101.PRE 11264
15 EXTRACTED XBRL INSTANCE DOCUMENT d911298d8k_htm.xml XML 3636
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 241574072
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)